Kyverna Therapeutics, Inc.

Direct answer

Kyverna Therapeutics, Inc. is publicly traded on NASDAQ under the ticker KYTX.

Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and lupus nephritis, as well as multiple sclerosis and systemic sclerosis. The company is also developing KYV-102, an...

Can you invest in Kyverna Therapeutics, Inc.?

Yes. Kyverna Therapeutics, Inc. trades publicly on NASDAQ as KYTX.

View deeper analysis

View detailed research on MarketSnap, including financials, valuation tools, and analyst context.

Open research for Kyverna Therapeutics, Inc.

Detailed equity research is provided by MarketSnap.